BSH/ISH 2016 | Application of molecular genetic testing in AML
Gail Roboz, MD from Weill Medical College of Cornell University, New York, NY discusses the availability of commercially available genetic molecular testing in which approximately 200 mutations can be evaluated. However current practice is exclusively guided by FLT3, NPM1, CEBPA double mutations. Availability of clinical trials for other specific mutations, for instance IDH1 and 2 , is making molecular genetic testing for these mutations more common practice in both prognosticating and driving treatment. Dr Roboz also discusses the application of molecular genetic testing in older acute myeloid leukemia (AML) patients. Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), in Glasgow, Scotland.
